Lisa A. Kachnic
Columbia University
289 Papers
2K Citations
Lisa A. Kachnic is an academic researcher from Columbia University. The author has contributed to research in topics: Radiation therapy & Medicine. The author has an hindex of 48, co-authored 251 publications. Previous affiliations of Lisa A. Kachnic include Dresden University of Technology & Emory University.
Chat about Author
Papers
RTOG 0436: A phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery.
David H. Ilson,Jennifer Moughan,Mohan Suntharalingam,Adam P. Dicker,Lisa A. Kachnic,Andre Konski,Bapsi Chakravarthy,Chris Anker,Harish V. Thakrar,Naomi Horiba,V.S. Kavadi,Melvin Deutsch,Adam Raben,Kevin S. Roof,John H. Suh,Jondavid Pollock,Howard Safran,Christopher H. Crane +17 more
TL;DR: Overall survival (OS) was the primary endpoint, with a planned accrual of 420 pts to detect an increase in 2-year OS from 41% to 53%; 80% power and 1-sided 0.025 alpha was planned.
36
CogState computerized memory tests in patients with brain metastases: secondary endpoint results of NRG Oncology RTOG 0933.
Chip Caine,Chip Caine,Snehal Deshmukh,Vinai Gondi,Minesh P. Mehta,Wolfgang A. Tomé,Benjamin W. Corn,Andrew A. Kanner,Howard Rowley,Vijayananda Kundapur,Albert S. DeNittis,Jeffrey Greenspoon,Andre Konski,Glenn Bauman,Adam Raben,Wenyin Shi,Merideth M Wendland,Lisa A. Kachnic +17 more
TL;DR: Study findings support the possibility that hippocampal avoidance may be associated with preservation of memory test performance, and that these computerized tests also may be useful and valid memory assessments in multi-institution adult brain tumor trials.
Efficacy endpoints of radiation therapy group protocol 0247: A randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer
Stuart J. Wong,Jennifer Moughan,Neal J. Meropol,Pramila R. Anne,Lisa A. Kachnic,Asif Rashid,James C. Watson,Edith P. Mitchell,Jondavid Pollock,R. Jeffrey Lee,Michael G. Haddock,Beth Erickson,Christopher G. Willett +12 more
TL;DR: Efficacy results for both arms are similar to other reported studies but suggest that pathologic complete remission is an unsuitable surrogate for traditional survival metrics of clinical outcome, and it remains uncertain whether the addition of a second cytotoxic agent enhances the effectiveness of fluorouracil plus RT.
Elective Clinical Target Volumes for Conformal Therapy in Anorectal Cancer: An RTOG Consensus Panel Contouring Atlas
Robert J. Myerson,Michael C. Garofalo,I. El Naqa,Ross A. Abrams,P. Das,Leonard L. Gunderson,Theodore S. Hong,J. Kim,Christopher G. Willett,Lisa A. Kachnic +9 more
TL;DR: A Radiation Therapy Oncology Group (RTOG) atlas of the elective clinical target volume (CTV) definitions to be used for planning pelvic intensity-modulated radiotherapy (IMRT) for anal and rectal cancers is developed.
32
Quality-of-Life Outcomes in Oncology
TL;DR: QOL outcomes have become an integral component of many clinical oncology trials and should focus on phase III trials with clear hypotheses that can lead to clinically meaningful interventions.
31